Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Poster Schedule
Home
Poster Schedule
All Days
Mon, Aug 26
Tue, Aug 27
Wed, Aug 28
Poster Schedule
Type here to filter the list
Wednesday, August 28, 2024
8:00 AM – 1:30 PM
CEST
(001) A comparison of regulatory frameworks for real-world data (RWD) collection within Early Access Programs (EAP) in the US, EU and Japan
Favorite
8:00 AM – 1:30 PM
CEST
(002) Breaking the Code: Patient Associations' Perception on Adverse Drug Reaction Reporting in Portugal
Favorite
8:00 AM – 1:30 PM
CEST
(003) Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research
Favorite
8:00 AM – 1:30 PM
CEST
(004) Challenges of multi-country post-authorisation safety studies for surveillance of new medical products
Favorite
8:00 AM – 1:30 PM
CEST
(005) Challenges, Lessons Learned and Implications for Improvement in Employing Drug Utilization Studies to Evaluate the Effectiveness of Additional Risk Minimization Measures (aRMMs)
Favorite
8:00 AM – 1:30 PM
CEST
(006) Comparative analysis of European healthcare systems: insights for selecting countries when designing Post-Authorization Safety Studies
Favorite
8:00 AM – 1:30 PM
CEST
(007) Comparative Analysis of Medicines Under Additional Monitoring in the European Union and Bulgaria
Favorite
8:00 AM – 1:30 PM
CEST
(008) Comparing regulatory guidance on risk mitigation (or RMM) studies and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies (RIMES) checklist
Favorite
8:00 AM – 1:30 PM
CEST
(009) Completion and reporting rates of paediatric clinical trials conducted as part of an EU Paediatric Investigation Plan.
Favorite
8:00 AM – 1:30 PM
CEST
(010) Comprehensive Analysis of Pharmacovigilance Inspections Practices: Focus on QPPV Responsibilities in the Pharmaceutical Industry in Saudi Arabia
Favorite
8:00 AM – 1:30 PM
CEST
(011) Does Expedited Regulatory Approval Predict the Therapeutic Value of Drugs? A Systematic Review
Favorite
8:00 AM – 1:30 PM
CEST
(012) Drivers and Methodological Considerations Associated with the Acceptability of Real-World Evidence for Effectiveness/Efficacy by Regulators and HTAs: Evidence from North America, Europe, and Australia
Favorite
8:00 AM – 1:30 PM
CEST
(013) Effectiveness of additional risk minimisation measures for valproate among healthcare professionals and patients: a cross-sectional survey in six European countries
Favorite
8:00 AM – 1:30 PM
CEST
(014) Experiences and perceptions of patients and healthcare professionals with advanced practice partnership agreements between Family Medicine Group pharmacists and healthcare professionals
Favorite
8:00 AM – 1:30 PM
CEST
(015) Experts’ opinion on data quality assessments for multi-database pharmacoepidemiologic studies: A qualitative analysis
Favorite
8:00 AM – 1:30 PM
CEST
(016) FDA REMS: Characterizing Burdens and Case Application of a Novel Integrated Ethical Framework
Favorite
8:00 AM – 1:30 PM
CEST
(017) Forging a Path for Transporting Real-World Evidence: Existing Applications & Proposed Practices
Favorite
8:00 AM – 1:30 PM
CEST
(018) Guidelines for the Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in Pharmacovigilance (READUS-PV)
Favorite
8:00 AM – 1:30 PM
CEST
(019) Health Technology Assessment in the Asia-Pacific Region: A Systematic Review of Current Practices, Challenges, and Future Directions
Favorite
8:00 AM – 1:30 PM
CEST
(020) Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: A comparison Between Manufacturer and Common Drug Review analyses
Favorite
8:00 AM – 1:30 PM
CEST
(021) How to improve Patient centricity in Benefit-Risk Assessments (BRA)?
Favorite
8:00 AM – 1:30 PM
CEST
(022) Impact of Mobile Health (mHealth) Technologies on Medication Adherence and Symptoms Improvement in Patients Receiving Oral Anti-Cancer Agents: A Systematic Review
Favorite
8:00 AM – 1:30 PM
CEST
(023) Impact of pharmacovigilance interventions targeting fluoroquinolones on systemic antimicrobial drug use and health outcomes in the Netherlands
Favorite
8:00 AM – 1:30 PM
CEST
(024) Impact of regulatory interventions on immediate release fentanyl and alternatives use in Spain: an interrupted time-series analysis
Favorite
8:00 AM – 1:30 PM
CEST
(025) Improving the Quality of Drug Safety Review Reports: SFDA Experience
Favorite
8:00 AM – 1:30 PM
CEST
(026) Medication Errors After Methotrexate Administration. An Analysis of EudraVigilance Reports Before and After EU Referral
Favorite
8:00 AM – 1:30 PM
CEST
(027) More-EUROPA (More Effectively Using Registries) – A cross-sectional survey assessing evidence needs around the introduction of new medicines
Favorite
8:00 AM – 1:30 PM
CEST
(028) Overview of regulations for INN prescribing and substitution, with implications for the implementation of crossborder ePrescription and eDIspensation services in countries of the European Union.
Favorite
8:00 AM – 1:30 PM
CEST
(029) Patient and Public Involvement in pharmacoepidemiological research: an environmental scan
Favorite
8:00 AM – 1:30 PM
CEST
(030) Pharmacogenomics-Pharmacovigilance Project: SFDA Experience
Favorite
8:00 AM – 1:30 PM
CEST
(031) Proactive Safety Monitoring of Recent Registered Medicinal Products in Saudi Arabia: the SFDA Experience
Favorite
8:00 AM – 1:30 PM
CEST
(032) Race and Ethnicity Variables in Real-World Data: Implications for Reproducibility in Pharmacoepidemiology.
Favorite
8:00 AM – 1:30 PM
CEST
(033) Review of Pharmacovigilance Practice of Biosimilars in Japan
Favorite
8:00 AM – 1:30 PM
CEST
(034) Scoping Review of the Use of Post-marketing Database Studies (PMDS) as an Additional Pharmacovigilance Activity of Risk Management Plans in Japan
Favorite
8:00 AM – 1:30 PM
CEST
(035) Study Design Considerations for Real-world Observational Studies Supporting Pre-Approval Regulatory Decision-making in China
Favorite
8:00 AM – 1:30 PM
CEST
(036) The ICH E9(R1) Estimand Framework in the Context of Real-World Data and Observational Studies
Favorite
8:00 AM – 1:30 PM
CEST
(037) The public health impact of suspending cyproterone acetate (2mg)/ethinylestradiol (35µg) in France: A predictive modelling technique to estimate adverse drug reactions prevented by regulatory action
Favorite
8:00 AM – 1:30 PM
CEST
(038) Unlocking Insights: Lesson Learned from the Tokenization of a Psoriasis Trial
Favorite
8:00 AM – 1:30 PM
CEST
(039) Use of Drug Use Evaluations by Australia’s National Reimbursement Agency to Assess Quality of Medicines Use: A Document Analysis Study
Favorite
8:00 AM – 1:30 PM
CEST
(040) Using Real-World Evidence for Clinical Drug Development to Address the Gap Between Marketing Authorization and Reimbursement in European Countries
Favorite
8:00 AM – 1:30 PM
CEST
(041) Utilizing the Delphi Consensus Method to Enhance Educational Materials for Healthcare Practitioners: A Case Study with Eylea
Favorite
8:00 AM – 1:30 PM
CEST
(042) What are the main experiences and treatment preferences of people living with achondroplasia and their caregivers?
Favorite
8:00 AM – 1:30 PM
CEST
(043) “Effect Of Pharmacological Interventions On Liver Function Parameters In Patients With NAFLD/NASH: A Systematic Review and Network meta-Analysis”
Favorite
8:00 AM – 1:30 PM
CEST
(044) A Comprehensive Meta-Analysis Assessing the Diagnostic Accuracy of Non-invasive Markers to Discriminate NAFLD and NASH
Favorite
8:00 AM – 1:30 PM
CEST
(045) Assessment of Readiness to Change in Individuals with Alcoholic Liver Disease: A Cross-Sectional Study in Indian Settings
Favorite
8:00 AM – 1:30 PM
CEST
(046) Associations between Laboratory Results and Mortality in Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Diabetes and Antihypertensive Drug Status.
Favorite
8:00 AM – 1:30 PM
CEST
(047) Characteristics and prevalence of potential inappropriate proton-pump-inhibitors users among older adults in Portugal: A nationwide retrospective study
Favorite
8:00 AM – 1:30 PM
CEST
(048) Cirrhosis Risk Prediction in individuals with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Favorite
8:00 AM – 1:30 PM
CEST
(050) Compared to Thiopurines and Tumor Necrosis Factor Inhibitors Novel Biologics Are Associated with Reduced Risk of Non-Melanoma Skin Cancer Among Patients with Inflammatory Bowel Disease
Favorite
8:00 AM – 1:30 PM
CEST
(051) Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: Impact of Study Design Differences on Treatment Effect
Favorite
8:00 AM – 1:30 PM
CEST
(052) Drug Repurposing in Crohn’s Disease using Danish real-world data
Favorite
8:00 AM – 1:30 PM
CEST
(053) Identification of Cohorts for Ulcerative Colitis, Diabetes, and Small Cell Lung Cancer With Corresponding Demographic and Geographic Distributions From a Nationally Representative U.S. Pharmacy Database
Favorite
8:00 AM – 1:30 PM
CEST
(054) Incidence Rates of Severe Acute Liver Injury Associated with Hepatotoxic Medication Combinations: Approach to Inform Future Drug-Drug Interaction Studies
Favorite
8:00 AM – 1:30 PM
CEST
(055) Measuring the Use of TNF-alpha Inhibitors in Patients with Ulcerative Colitis: Optimization of Washout Period Duration and Observability
Favorite
8:00 AM – 1:30 PM
CEST
(056) Non-Alcoholic Steatohepatitis (NASH) as a Risk Factor in Hepatocellular Carcinoma (HCC) Development
Favorite
8:00 AM – 1:30 PM
CEST
(057) Spatial-Temporal Patterns In Biologic Prescriptions For Inflammatory Bowel Diseases In The Public Healthcare System In Brazil
Favorite
8:00 AM – 1:30 PM
CEST
(058) Surgery for Chronic Diverticular Disease - Incidence and Predictors
Favorite
8:00 AM – 1:30 PM
CEST
(059) The Incidence of Immune Checkpoint Inhibitor-Related Hepatotoxicity (ICH) in a Real-World Setting: A Retrospective Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(060) Addressing Drug-Related Issues in Elderly Patients: A Prospective Interventional Study
Favorite
8:00 AM – 1:30 PM
CEST
(062) Assessment of Drug Therapy Satisfaction Using Treatment Satisfaction with Medicines Questionnaire (SATMED Q)
Favorite
8:00 AM – 1:30 PM
CEST
(063) Association between Polypharmacy and the Risk of Chronic Kidney Disease in the Elderly Patients
Favorite
8:00 AM – 1:30 PM
CEST
(064) Battle of the Bisphosphonates: Global Utilization Trends for Osteoporosis between 2011 and 2022
Favorite
8:00 AM – 1:30 PM
CEST
(065) Bisphosphonates versus Denosumab: Assessing the Risk of Heart Failure in a Nationwide Retrospective Cohort Study in Taiwan
Favorite
8:00 AM – 1:30 PM
CEST
(066) Changes in long-term glucocorticoid use among older adults after new diagnosis of late-onset rheumatoid arthritis
Favorite
8:00 AM – 1:30 PM
CEST
(067) Clinical outcomes of discontinuing long-term opioid therapy among older cancer survivors in nursing homes
Favorite
8:00 AM – 1:30 PM
CEST
(068) Contemporary Management of Patients After Hip Fracture. A Population-Based Cohort of Over 120.000 Patients in Spain.
Favorite
8:00 AM – 1:30 PM
CEST
(069) Denosumab Data Cleaning Algorithm to Inform Exposure Measurement and Study Inclusion: Results from Two International Databases
Favorite
8:00 AM – 1:30 PM
CEST
(070) Disability Phenotypes among Medicare Beneficiaries with Dementia: Implications for Longitudinal Confounding Control, Risk Stratification, and Comparative Effectiveness Research
Favorite
8:00 AM – 1:30 PM
CEST
(071) Discontinuation of bisphosphonates in older people with complex health needs: self-controlled case series to assess fracture risk
Favorite
8:00 AM – 1:30 PM
CEST
(072) Drug Holiday of Oral Bisphosphonates and Mortality following Hip Fracture: A Population-based Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(073) Effects of AI-Assisted Drug Therapy Management on Medication-Related Issues in Elderly Patients: A Systematic Review
Favorite
8:00 AM – 1:30 PM
CEST
(074) Identification of Inappropriate Prescribing in Elderly Population Using Medication Appropriateness Index (MAI) and Beer’s Criteria
Favorite
8:00 AM – 1:30 PM
CEST
(075) Impact of Awareness of Osteoporosis and BMD Testing on Osteoporosis Medication Use in Elderly Men and Women with Osteoporosis
Favorite
8:00 AM – 1:30 PM
CEST
(076) Incidence of opioid dose tapering among older adults enrolled in Medicare
Favorite
8:00 AM – 1:30 PM
CEST
(077) Large scale propensity score matching with time-stratification in older women with or without fractures in the UK
Favorite
8:00 AM – 1:30 PM
CEST
(078) Lifetime risk of fracture among postmenopausal women with osteoporosis and at high risk of fracture
Favorite
8:00 AM – 1:30 PM
CEST
(079) Medication Use Patterns Among Older Adults With Obstructive Sleep Apnea With and Without Comorbid Insomnia
Favorite
8:00 AM – 1:30 PM
CEST
(080) Opioid Deprescribing Rates in Older Adults with Frailty and Risk Factors for Prolonged Use after an Acute Fracture
Favorite
8:00 AM – 1:30 PM
CEST
(081) Patterns of Concurrent Opioid and Benzodiazepine Use Discontinuation among Medicare Beneficiaries 2016-2018
Favorite
8:00 AM – 1:30 PM
CEST
(082) Prevalence And Patterns of Drug-Related Problems Associated with Polypharmacy in Elderly Patients with Heart Failure: A Prospective Interventional Study
Favorite
8:00 AM – 1:30 PM
CEST
(083) Trajectories of Analgesic Agent Use and Adverse Clinical Outcomes Among Older Adults: a Nationwide Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(084) Trends in Central Nervous System Medication Use among Assisted Living Residents with Cognitive Impairment: Variation by Presence of Dementia Care and the COVID-19 Pandemic
Favorite
8:00 AM – 1:30 PM
CEST
(085) An Assessment of Use and Comparative Safety of GLP-1 Receptor Agonists in the Real-world Setting, 2017-2023
Favorite
8:00 AM – 1:30 PM
CEST
(086) Applying Natural Language Processing of Clinical Notes to Determine Social Determinant Risk Factor Status for Patients Receiving Glucagon-Like Peptide-1 Agonist Treatment
Favorite
8:00 AM – 1:30 PM
CEST
(087) Assessment of the Long-Term Stability of Drug Safety Signals between Frequency and Bayesian-based methods for Glucagon-like Peptide-1 Receptor Agonists
Favorite
8:00 AM – 1:30 PM
CEST
(088) Association of Glucagon-Like Peptide-1 Receptor Agonists with Parkinson’s Disease: Scandinavian Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(089) Characteristics of Glucagon-Like Peptide-1 Agonist Prescriptions for Weight Loss in the Real-World Setting
Favorite
8:00 AM – 1:30 PM
CEST
(090) Characteristics of Initial Prescription Dispensations Among Individuals Newly Prescribed GLP-1 Medications in a National Retail Pharmacy Database
Favorite
8:00 AM – 1:30 PM
CEST
(091) Characterizing the use of weight loss medications in people with obesity-related asthma in the All of Us Research Program
Favorite
8:00 AM – 1:30 PM
CEST
(092) Comparing Healthcare Utilization and Cost in Empagliflozin vs GLP-1RA Initiators with Type 2 Diabetes without Established Cardiovascular Disease
Favorite
8:00 AM – 1:30 PM
CEST
(093) Effectiveness of GLP-1 Receptor Agonists on Bodyweight Among Patients with Type-2 Diabetes Mellitus: Emulation of Five Randomized Clinical Trials Using Electronic Medical Records
Favorite
8:00 AM – 1:30 PM
CEST
(094) Effectiveness of the GLP-1 Receptor Agonists Approved to Manage Overweight and Obesity: An Emulation of the STEP 8 Trial Using Electronic Medical Records
Favorite
8:00 AM – 1:30 PM
CEST
(095) Gastrointestinal Adverse Events with Glucagon-like Peptide-1 Receptor Agonist in Type 2 Diabetes: A Comprehensive Meta-analysis of Randomised Controlled Trials and Refining Signals through Pharmacovigilance Analysis.
Favorite
8:00 AM – 1:30 PM
CEST
(096) GLP1 comparative effectiveness against dementia onset in a large, multi-site cohort of type 2 diabetes patients: a trial emulation approach with targeted learning
Favorite
8:00 AM – 1:30 PM
CEST
(097) Real-World Patterns in GLP-1 RA Switching from 2018-2023 in the US
Favorite
8:00 AM – 1:30 PM
CEST
(099) Treatment Trends in Youth-Onset Type 2 Diabetes: Changing Landscape After GLP-1RA Approval
Favorite
8:00 AM – 1:30 PM
CEST
(100) Trends in Clinical Characteristics and Prescribing Patterns for GLP-1 Receptor Agonists and GIPs, 2015–2023
Favorite
8:00 AM – 1:30 PM
CEST
(101) Use of SGLT2 inhibitors vs. GLP-1 RAs and Asthma Exacerbation in Patients with Diabetes and Asthma – A target Trial Emulation Study
Favorite
8:00 AM – 1:30 PM
CEST
(102) Utilization of drugs with weight loss effect in Norway 2017-2023
Favorite
8:00 AM – 1:30 PM
CEST
(103) Weight Loss Medication Prescribing Patterns: Real-World Data Analysis from 2015 to 2023
Favorite
8:00 AM – 1:30 PM
CEST
(104) Determining the cost-effectiveness of pre-emptive genetic testing: an umbrella review
Favorite
8:00 AM – 1:30 PM
CEST
(105) Prescription Medicine Price Comparison of Employer-Sponsored Health Insurance versus Public Procurement System Used in The National Health Insurance in Indonesia
Favorite
8:00 AM – 1:30 PM
CEST
(106) Prevalence, incidence rate and attributable healthcare costs of four major disease groups in Denmark: A nationwide cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(107) Bridging the Gap and Ensuring Quality: Enhancing Real-World Data through Quality Control Implementation of an African Patient Population
Favorite
8:00 AM – 1:30 PM
CEST
(108) Comparing the Association of Social Determinants of Health between Hypertension, Migraine, and Coexisting Hypertension and Migraine in U.S. Adults Using Medical Expenditure Panel Survey Data (2013-2019)
Favorite
8:00 AM – 1:30 PM
CEST
(109) Measuring Health Trends of Transgender People Using Real World Data in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(110) Postpartum Depression and Infant Vaccination Completion: A Real-World Data and Health Equity Perspective
Favorite
8:00 AM – 1:30 PM
CEST
(111) Prevalence of Polypharmacy, Multimorbidity and Association with Mortality in Older Aboriginal and Torres Strait Islander People.
Favorite
8:00 AM – 1:30 PM
CEST
(112) Racial Disparities in Breast Cancer Management Pre- and Post-COVID-19: Unmet Needs in Health Equity
Favorite
8:00 AM – 1:30 PM
CEST
(113) Racial disparities in survival among low-income populations with lung, breast, prostate or colorectal cancers across the Southeastern United States
Favorite
8:00 AM – 1:30 PM
CEST
(114) Racial Disparity in Comorbidity Risk Profiles of Early-Onset Liver Cancer: A Case-Control Study Based on the University of California Healthcare Data Warehouse
Favorite
8:00 AM – 1:30 PM
CEST
(115) A Critical Methodological Appraisal of Studies Assessing Computerized Clinical Decision Support Systems (CDSS) Success in Improving Prescription Safety in Patients with Low Levels of Kidney Function
Favorite
8:00 AM – 1:30 PM
CEST
(116) Case-Identifying Algorithms of Chronic Kidney Disease for Real-World Evidence Research: A Targeted Literature Review
Favorite
8:00 AM – 1:30 PM
CEST
(117) Effectiveness of pharmacist intervention in patients with pre-end-stage renal disease (pre-ESRD): A prospective study
Favorite
8:00 AM – 1:30 PM
CEST
(118) Ethnicity and polypharmacy in people with chronic kidney disease: a pharmacoepidemiologic perspective
Favorite
8:00 AM – 1:30 PM
CEST
(120) Living alone and prognosis in elderly patients with chronic kidney disease: a nationwide study from Denmark
Favorite
8:00 AM – 1:30 PM
CEST
(121) Mortality associated with use of etelcalcetide versus cinacalcet for the treatment of secondary hyperparathyroidism in patients in haemodialysis: a population based study in Lazio, Italy
Favorite
8:00 AM – 1:30 PM
CEST
(122) Multisource Overview on Proton Pump Inhibitors-Associated Acute Kidney Injury
Favorite
8:00 AM – 1:30 PM
CEST
(123) Predictors of post-operative acute kidney injury after colorectal cancer surgery
Favorite
8:00 AM – 1:30 PM
CEST
(124) Risk Modeling to Obtain Individualized Estimates of Ibuprofen Associated Acute Kidney Injury in Hospitalized Patients
Favorite
8:00 AM – 1:30 PM
CEST
(125) Risk of Acute Kidney Injury with Direct Oral Anticoagulants Compared with Warfarin: Population-based analysis.
Favorite
8:00 AM – 1:30 PM
CEST
(126) Risk of Peritonitis in Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis
Favorite
8:00 AM – 1:30 PM
CEST
(127) Selective reporting of renal effects in clinical trials with cyclooxygenase-2 inhibitors
Favorite
8:00 AM – 1:30 PM
CEST
(128) Sex-specific temporal trends in prevalence and incidence of chronic kidney disease: a Danish population-based cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(129) Short- and Long-Term Associations of Hyperkalemia-related Events on Serum Potassium Time Courses in Patients with Chronic Kidney Disease: A Retrospective Cohort Study Using Electronic Health Records Data from the United States
Favorite
8:00 AM – 1:30 PM
CEST
(130) A comparison of the descriptive epidemiology derived from the GOLD and Aurum datasets in the Clinical Practice Research Datalink
Favorite
8:00 AM – 1:30 PM
CEST
(131) A Flexible Open-Source Analytic Pipeline for Self-Controlled Analysis of Real World Data
Favorite
8:00 AM – 1:30 PM
CEST
(132) A Framework for Rapid Analysis of Real-World Data in Safety Signal Assessment
Favorite
8:00 AM – 1:30 PM
CEST
(133) A novel estimation method for adjusting virtual inconsistency in a star-shaped network meta-analysis: an illustration of a case study
Favorite
8:00 AM – 1:30 PM
CEST
(134) A review of recommendations in guidelines on missing data in prediction modelling
Favorite
8:00 AM – 1:30 PM
CEST
(135) A semi-quantitative method to assess the likelihood of causality in observational studies
Favorite
8:00 AM – 1:30 PM
CEST
(136) A systematic review of algorithms used to identify neurodevelopmental disorders in electronic healthcare databases
Favorite
8:00 AM – 1:30 PM
CEST
(137) A Systematic Review to Summarize and Critically Appraise of Existing Phenotype Libraries Using Electronic Health Records- a FLOW study under the VAC4EU organisation
Favorite
8:00 AM – 1:30 PM
CEST
(138) An Application of Bayesian Modelling for Information Sharing in Safety Signal Detection
Favorite
8:00 AM – 1:30 PM
CEST
(139) An Evaluation of Patient Activity Definitions and Informative Censoring in Analyses of Real-World Overall Survival in Electronic Health Records (EHR) in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(140) Application of capture-recapture method to estimate prevalence with registry data
Favorite
8:00 AM – 1:30 PM
CEST
(141) Assessing Exposure to Recently Approved Medications to Inform Feasibility for Signal Identification Analyses in the FDA’s Sentinel System
Favorite
8:00 AM – 1:30 PM
CEST
(142) Assessing the potential value of commercial mortality data combined with publicly available death data for pharmacoepidemiology research
Favorite
8:00 AM – 1:30 PM
CEST
(143) Assessment of the Application of a 90-Day-Gap Rule for Mitigating Frontline Treatment Sequence Misclassification in Electronic Health Records in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(144) Comparison of multilevel propensity score estimation methods for tooth-clustered data in the evaluation of treatment effect in the presence of competing risks
Favorite
8:00 AM – 1:30 PM
CEST
(145) Critical Review of Dimensionality Reduction Approaches in Epidemiological Research
Favorite
8:00 AM – 1:30 PM
CEST
(146) Development and Indirect Validation of Patient Identification Algorithms to Identify Patients with Refractory Lupus using US Insurance Claims
Favorite
8:00 AM – 1:30 PM
CEST
(147) Development and Validation of a Novel Tool to Predict Hemoglobin A1c among Patients with Type 2 Diabetes, Using Administrative Claims Data
Favorite
8:00 AM – 1:30 PM
CEST
(148) Development and Validation of Text Mining Approach for Detecting Recurrence for Early Breast Cancer Patients: A Multi-institutional Study in Taiwan
Favorite
8:00 AM – 1:30 PM
CEST
(149) Development of Algorithms for the Implementation and Detection of Adverse Events in Routine Electronic Data Sources
Favorite
8:00 AM – 1:30 PM
CEST
(150) Effect of Race on Classification of Atherosclerotic Risk Using A National Cardiovascular Risk Prediction Tool
Favorite
8:00 AM – 1:30 PM
CEST
(151) Enhancing Evidence Generation by Linking Randomized Clinical Trials to Real-World Data: A Validation Study from the INVESTED-Medicare Linkage
Favorite
8:00 AM – 1:30 PM
CEST
(152) Evaluating Methods to Define Place of Residence in Administrative Data and the Impact on Observed Associations
Favorite
8:00 AM – 1:30 PM
CEST
(153) Evaluating the Accuracy of Infant Weight and Length Measurements from Electronic Health Records for Use in Maternal Vaccination Safety Studies
Favorite
8:00 AM – 1:30 PM
CEST
(154) Fit-for-purpose evaluation of Real-World Data for vaccines and medicines safety studies: the INSIGHT tool
Favorite
8:00 AM – 1:30 PM
CEST
(155) Guidance for the Design of Observational Studies to Estimate the Effects of Long-term Drug Exposures
Favorite
8:00 AM – 1:30 PM
CEST
(156) High-dimensional propensity score implementation utilising electronic health records in Hong Kong
Favorite
8:00 AM – 1:30 PM
CEST
(157) Identification and Quantification of Barriers to Achieving Clinical Trial Diversity
Favorite
8:00 AM – 1:30 PM
CEST
(158) Identification of Valid Indicators for the Detection of Potentially Adverse Drug Event-Related Hospitalisations in Routine Electronic Data Sources: a RAND Survey
Favorite
8:00 AM – 1:30 PM
CEST
(159) Insomnia Symptom Prevalence in England: A Comparison of Self-Reported Data and Primary Care Records in the UK Biobank
Favorite
8:00 AM – 1:30 PM
CEST
(160) Intention to treat and on treatment exposure definition in observational safety studies: a simulation study using real world data
Favorite
8:00 AM – 1:30 PM
CEST
(161) Linking clinical trial participants to their U.S. real-world data through tokenization: a practical guide
Favorite
8:00 AM – 1:30 PM
CEST
(163) Methodological framework to conduct outcome validation in administrative or insurance claims and/or electronic healthcare record databases: a practical guide for pharmacoepidemiologists
Favorite
8:00 AM – 1:30 PM
CEST
(165) Missing data analysis methods to correct outcome mismeasurement in pharmacoepidemiological studies using electronic medical information: Methodologies and recommendations for future validation studies
Favorite
8:00 AM – 1:30 PM
CEST
(166) Model-based Meta-analysis: An Innovative and Robust Methodology for Clinical Decision Making
Favorite
8:00 AM – 1:30 PM
CEST
(167) Optimizing BMI Data Accuracy: Synergy Of Claims And EHR Databases
Favorite
8:00 AM – 1:30 PM
CEST
(168) Outcome Validation to Assess Misclassification Bias in Studies Using Electronic Healthcare Claims
Favorite
8:00 AM – 1:30 PM
CEST
(169) Quantification of information gained by linking claims data to an EHR cohort of US metastatic breast cancer (mBC) patients
Favorite
8:00 AM – 1:30 PM
CEST
(170) Quantifying Bias in Claims Safety Studies Arising from Medication Samples: A Simple Simulation
Favorite
8:00 AM – 1:30 PM
CEST
(171) Quantifying the impact of different look-back period criteria to identify new users when medication adherence is poor: A study of chronic medications for opioid use disorder
Favorite
8:00 AM – 1:30 PM
CEST
(172) Reporting of Harm from Randomized Clinical Trials in Medical Publications
Favorite
8:00 AM – 1:30 PM
CEST
(173) Short-term mortality in the Danish Better Health in Late Life Cohort - A study on cohort representativeness
Favorite
8:00 AM – 1:30 PM
CEST
(174) Standardization of Coding Definitions for Sickle Cell Disease Complications: A Systematic Literature Review
Favorite
8:00 AM – 1:30 PM
CEST
(175) The Use and Implementation of Instrumental Variables in Pharmacoepidemiology: A Scoping Review
Favorite
8:00 AM – 1:30 PM
CEST
(176) Translating population-level epidemiology to patient need
Favorite
8:00 AM – 1:30 PM
CEST
(177) Validated case-identifying algorithms using Canadian administrative health data: a targeted literature review
Favorite
8:00 AM – 1:30 PM
CEST
(178) Validation of Algorithms to Identify Breast Cancer and Bladder Cancer Among Patients With Type 2 Diabetes Mellitus in United States Medicare Administrative Claims
Favorite
8:00 AM – 1:30 PM
CEST
(179) Validation of claims algorithm to identify HR+/HER2- metastatic breast cancer patients
Favorite
8:00 AM – 1:30 PM
CEST
(180) Validation of claims-based algorithms for identifying neonatal urinary tract, genital, gastrointestinal, and musculoskeletal malformations in healthcare utilization databases
Favorite
8:00 AM – 1:30 PM
CEST
(181) Validation of obstetric diagnosis and procedure codes in the Danish National Patient Registry
Favorite
8:00 AM – 1:30 PM
CEST
(182) Validation of Rhabdomyolysis in Claims Using Electronic Health Data in Taiwan
Favorite
8:00 AM – 1:30 PM
CEST
(183) Validation study of the death information registered in BIFAP electronic health care records data source (Spain).
Favorite
8:00 AM – 1:30 PM
CEST
(184) Validity of Inpatient ICD 10 Codes for Heat-related Illnesses in US Medicare Data
Favorite
8:00 AM – 1:30 PM
CEST
(185) Validity of Out-of-Hospital and In-Hospital Cardiac Arrest Algorithms in the Danish National Patient Registry
Favorite
8:00 AM – 1:30 PM
CEST
(186) Who Should Be Prioritised For Primary Care Medication Review? Consensus Validation And Point Prevalence of Explicit Prescribing Indicators
Favorite
8:00 AM – 1:30 PM
CEST
(187) Will Patients engage with Digiatl Technologies as part of Routine Healthcare?
Favorite
8:00 AM – 1:30 PM
CEST
(188) Association between antidepressants and risk of withdrawal syndrome in illicit substance users: nationwide case-case-time-control study
Favorite
8:00 AM – 1:30 PM
CEST
(189) Disability and Workers’ Compensation Absences Associated with Major Depressive Disorder and the Overlap with Family Medical Leaves Among US Employees
Favorite
8:00 AM – 1:30 PM
CEST
(190) Do efficacy results obtained from randomised controlled trials translate to effectiveness data from observational studies for relapsing-remitting multiple sclerosis?
Favorite
8:00 AM – 1:30 PM
CEST
(191) Healthcare resource use (HRU) of patients with active relapsing multiple sclerosis (RMS) using data linkage between a phase IV study and the France's national health data system.
Favorite
8:00 AM – 1:30 PM
CEST
(192) Impact of the disability status of patients with multiple sclerosis on healthcare resource utilization and the ability to work: An analysis of the MSDS-AOK PLUS Linked Database
Favorite
8:00 AM – 1:30 PM
CEST
(193) Inflammatory Bowel Disease among Patients with Multiple Sclerosis and matched Controls: Findings from a Retrospective Cohort Study Utilizing a US Electronic Health Record Database
Favorite
8:00 AM – 1:30 PM
CEST
(194) Risk Of Cardiovascular Events Among Youths And Young Adults With Concomitant Use Of Atypical Antipsychotics With Antidepressants
Favorite
8:00 AM – 1:30 PM
CEST
(195) Systematic emulation trials to evaluate the real-world effectiveness of multiple sclerosis treatments
Favorite
8:00 AM – 1:30 PM
CEST
(196) The relative risk of infection in people with multiple sclerosis using disease-modifying treatments: a systematic review of observational studies
Favorite
8:00 AM – 1:30 PM
CEST
(197) The Risk of Hypokalemia in Patients Treated with Levetiracetam: A Comparative Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(199) A US Retrospective Claims Database Analysis: 2-year Restricted Mean Time in Buprenorphine Treatment Among People with Opioid Use Disorder
Favorite
8:00 AM – 1:30 PM
CEST
(200) Age-related risk of serious fall events associated with opioid analgesic use
Favorite
8:00 AM – 1:30 PM
CEST
(201) Association between long-term opioid use and risk of depression, suicidal ideation and sleep disorders in patients with fibromyalgia: a population-based, propensity-weighted cohort study.
Favorite
8:00 AM – 1:30 PM
CEST
(202) Association Between Rapid Opioid Dose Tapering and Polydrug Overdose Death Among High-dose, Long-term Opioid Therapy Recipients in North Carolina Between 2006-2018
Favorite
8:00 AM – 1:30 PM
CEST
(203) Association of opioid and benzodiazepine co-prescribing with adverse events among older adults with cancer
Favorite
8:00 AM – 1:30 PM
CEST
(205) Co-Administration of Oxycodone and CYP3A4-Inhibiting Calcium Channel Blockers and Opioid Overdose: Real-World Evidence from Population-based Claims Data in the United States, 2000-2020.
Favorite
8:00 AM – 1:30 PM
CEST
(206) Design Process for a Machine-Learning Opioid Overdose Prediction and Risk Stratification E-Tool in Electronic Health Record System
Favorite
8:00 AM – 1:30 PM
CEST
(207) Disenrollment Among Commercially-Insured Individuals in the United States with Opioid Use Disorder, 2010-2019
Favorite
8:00 AM – 1:30 PM
CEST
(208) Early Opioid Use Disorder Treatment Pathways and Determinants Among the Commercially-Insured, 2010-2019
Favorite
8:00 AM – 1:30 PM
CEST
(210) Long-term prescribed opioid use after hospitalisation or emergency department presentation among opioid-naïve adults in New South Wales (NSW), Australia (2014–2020)—a population-based cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(211) Machine Learning Natural Language Processing Classifiers to Enhance Opioid Overdose Surveillance Precision
Favorite
8:00 AM – 1:30 PM
CEST
(212) Medications for Opioid Use Disorder (MOUD) Prescribing Trends in the US Ambulatory Care Settings
Favorite
8:00 AM – 1:30 PM
CEST
(213) Opioid exit plans: A systematic review on tapering strategies upon hospital discharge for non-cancer pain
Favorite
8:00 AM – 1:30 PM
CEST
(215) Opioid Use and Its Association with Clostridium difficile Infection: A Systematic Review and Meta-Analysis of Observational Studies
Favorite
8:00 AM – 1:30 PM
CEST
(216) Patterns of inpatient opioid trajectories following major or orthopaedic surgery
Favorite
8:00 AM – 1:30 PM
CEST
(217) Patterns of opioid doses to compensated Australian workers with low back pain
Favorite
8:00 AM – 1:30 PM
CEST
(218) Perceptions on treatment utilization and risk of overdose among opioid users in Kolkata: A qualitative study
Favorite
8:00 AM – 1:30 PM
CEST
(219) Person, hospital, and geographic factors associated with connection to treatment following hospital discharge for an opioid toxicity
Favorite
8:00 AM – 1:30 PM
CEST
(220) Predictors of persistent opioid use in Australian primary care: a retrospective cohort study, 2018 – 2022
Favorite
8:00 AM – 1:30 PM
CEST
(221) Preoperative opioid use and postoperative return to work following spinal surgery in workers’ compensation settings: A systematic review and meta-analysis
Favorite
8:00 AM – 1:30 PM
CEST
(222) Prevalence and variations of potential hazardous opioid prescribing across the United Kingdom general practices
Favorite
8:00 AM – 1:30 PM
CEST
(223) Risk of post-surgical persistent opioid use and fractures in patients undergoing major surgery in England
Favorite
8:00 AM – 1:30 PM
CEST
(224) Use of medications for opioid use disorder in older adults
Favorite
8:00 AM – 1:30 PM
CEST
(225) A systematic review and network meta-analysis of gamification approach for attention-deficit hyperactivity disorder in children and adolescents focusing on digital therapeutics
Favorite
8:00 AM – 1:30 PM
CEST
(226) Adrenocorticotropic hormone versus prednisolone for infantile spasms: a systematic review and economic evaluation
Favorite
8:00 AM – 1:30 PM
CEST
(227) Assessment of Age-appropriateness and Acceptability of Oral Medicine Formulations for Children Less than 5 Years in a Low Income Setting
Favorite
8:00 AM – 1:30 PM
CEST
(228) Beta-blocker-associated Hypoglycemia in Pediatric Patients: Findings from the FDA Adverse Event Reporting System, National Poison Data System, Medical Literature, and Sentinel Distributed Database
Favorite
8:00 AM – 1:30 PM
CEST
(229) Characterizing incident antidepressant use in young people in Norway: pathways to treatment and follow-up in specialist healthcare
Favorite
8:00 AM – 1:30 PM
CEST
(230) Characterizing Infants in the Sentinel Distributed Database Mother-Infant Linkage Table
Favorite
8:00 AM – 1:30 PM
CEST
(231) Characterizing inpatient electronic health records (EHR) from a large hospital network for use in neonatal pharmacoepidemiology studies in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(232) Characterizing Pediatric Members in the Sentinel Distributed Database: An Update with Data from Medicaid
Favorite
8:00 AM – 1:30 PM
CEST
(233) Development of a multivariate prognostic model to predict mortality in neonatal sepsis patients.
Favorite
8:00 AM – 1:30 PM
CEST
(234) Dosing of antidepressants in relation to body weight in children and adolescents with overweight and obesity- a population-based study
Favorite
8:00 AM – 1:30 PM
CEST
(235) Drug utilization in children at a German university hospital – Are evidence-based (off-label) dosing recommendations available?
Favorite
8:00 AM – 1:30 PM
CEST
(236) Increased Prescribing of Neuroleptics to Children in Sweden
Favorite
8:00 AM – 1:30 PM
CEST
(237) Infant Growth and Development Outcomes among Commercially Insured Infants in the United States, 2016 – 2023
Favorite
8:00 AM – 1:30 PM
CEST
(238) Influence of relative age on initiation of methylphenidate and speech therapy in children aged 5 to 10 years: a French nationwide cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(239) Off-label use of antidepressants among pediatric patients in China
Favorite
8:00 AM – 1:30 PM
CEST
(240) Off-label use of thalidomide in pediatric patients with Crohn's disease and other subtypes of inflammatory bowel disease: a literature review
Favorite
8:00 AM – 1:30 PM
CEST
(241) Pediatric cancer in the United States: a comparison of two data sources
Favorite
8:00 AM – 1:30 PM
CEST
(242) Performance of Disease Activity Monitoring in Individuals with Childhood-Onset Lupus Nephritis in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(243) Prevalence and Patterns of ADHD Medication Use Among Children, Adolescents, and Young Adults: A Two-decade Analysis
Favorite
8:00 AM – 1:30 PM
CEST
(244) Psychotropic drug use among 0-17 year old Norwegians during 2014-2021: a nationwide register study
Favorite
8:00 AM – 1:30 PM
CEST
(245) Psychotropic Drug Utilization Patterns among Children and Adolescents in British Columbia, Canada: Sex Differences in Drug Initiation
Favorite
8:00 AM – 1:30 PM
CEST
(246) Quality assessment of medication data from routine paediatric inpatient documentation – A prerequisite for drug utilisation studies
Favorite
8:00 AM – 1:30 PM
CEST
(247) Relative age effect on ADHD diagnosis, medication prescription, and persistence: a population-based study within a birth cohort
Favorite
8:00 AM – 1:30 PM
CEST
(248) Surveillance of outcomes identified with use of biologics indicated for asthma: a comparison of events observed with pediatric utilization
Favorite
8:00 AM – 1:30 PM
CEST
(249) The importance of the analysis of multiple databanks for the valid estimation of thrombocytopenia incidence rates in children in BIFAP data source (Spain).
Favorite
8:00 AM – 1:30 PM
CEST
(250) The Pharmacotherapy Options for Attention-Deficit Hyperactivity Disorder (ADHD) in Taiwan and the Influencing Factors
Favorite
8:00 AM – 1:30 PM
CEST
(251) The real-world use of medicines for the management of haematological malignancies in paediatric populations: an international scoping review.
Favorite
8:00 AM – 1:30 PM
CEST
(252) Trends in Childhood BMI, Overweight, and Obesity among 7-year-old Girls during the Last Six Decades
Favorite
8:00 AM – 1:30 PM
CEST
(253) Trends in distal radius fractures in Japanese children 2007-2021
Favorite
8:00 AM – 1:30 PM
CEST
(254) Trends in New Use of Disease-Modifying Antirheumatic Drugs Among Children with Juvenile Idiopathic Arthritis in the United States, 2001-2022
Favorite
8:00 AM – 1:30 PM
CEST
(255) Trends of Antidepressant Use Among Children in Commercial and Public Payer Systems in the United States, 2001-2019
Favorite
8:00 AM – 1:30 PM
CEST
(256) Use of Medications with Depression and Suicidal Adverse Effects Among Children, Adolescents, and Young Adults in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(257) Within-Trial Interviews to Contextualize the Patient Experience and Supplement Clinical Outcomes Assessments in a Pivotal Trial of a Newly Described, Fatal and Ultra-Rare Pediatric Disease
Favorite
8:00 AM – 1:30 PM
CEST
(259) A Multi-Source Approach to Pregnancy and Lactation Evidence Generation in Multiple Sclerosis: The Ocrelizumab Example
Favorite
8:00 AM – 1:30 PM
CEST
(260) A systematic review of gabapentinoids use during pregnancy and effects on pregnancy and childhood outcomes: an IMI ConcePTION study
Favorite
8:00 AM – 1:30 PM
CEST
(262) Antidepressant and Psychotherapy Initiation Among Patients with New Episodes of Depression During Pregnancy
Favorite
8:00 AM – 1:30 PM
CEST
(263) Antiseizure medication use during pregnancy and the Risk of adverse neonatal birth outcomes in two Canadian provinces
Favorite
8:00 AM – 1:30 PM
CEST
(264) Cardiac Autonomic Stress Response in 6- and 12-Year-Old Children After Prenatal Selective Serotonin Reuptake Inhibitor Medication Exposure: A Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(265) Characteristics and Adverse Postpartum Psychiatric Outcomes in Women With Bipolar Disorder Who Discontinue Lithium During Pregnancy: A Swedish Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(266) Characteristics and Depression Severity Among Pregnant Women by Antidepressant Use During Pregnancy
Favorite
8:00 AM – 1:30 PM
CEST
(267) Characteristics of perinatal depression screening and trend over time in a commercial, US-based administrative claims database
Favorite
8:00 AM – 1:30 PM
CEST
(268) Comparative safety of prenatal exposure to buprenorphine versus methadone with regards to adverse neurodevelopmental outcomes
Favorite
8:00 AM – 1:30 PM
CEST
(269) Comparison of antidepressant use in normal-age and late-age pregnancies
Favorite
8:00 AM – 1:30 PM
CEST
(270) Concomitant Periconceptional Opioid Medication, Alcohol, and Tobacco Use
Favorite
8:00 AM – 1:30 PM
CEST
(271) Discontinuation patterns of antipsychotics in pregnant women: A cohort study from South Korea
Favorite
8:00 AM – 1:30 PM
CEST
(272) Emergency Department Visits due to Monoclonal Antibody Adverse Events—United States, 2004–2020
Favorite
8:00 AM – 1:30 PM
CEST
(273) Gabapentin in Pregnancy and Birth Outcomes: a Population-based Prevalence Study in Nordic Countries (EUPAS38620)
Favorite
8:00 AM – 1:30 PM
CEST
(274) Gabapentin Use During Pregnancy and the Risk of Adverse Neonatal Birth Outcomes in two Canadian provinces
Favorite
8:00 AM – 1:30 PM
CEST
(275) Gabapentinoids exposure in early pregnancy and risk of congenital anomalies: an IMI ConcePTION European case-malformed control study
Favorite
8:00 AM – 1:30 PM
CEST
(276) Intensity and duration antidepressant exposure in pregnancy and childhood growth trajectories: results from the Norwegian Mother, Father and Child Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(277) Maternal Mental Health in Focus: Real-World Data on Antidepressant Use. A Cohort Study in Catalonia.
Favorite
8:00 AM – 1:30 PM
CEST
(278) Maternal opioid use during breastfeeding and the risk of adverse infant outcomes: A nationwide cohort study among 4 million mother-child dyads
Favorite
8:00 AM – 1:30 PM
CEST
(279) Opioid Use in Pregnancy in Women with Disabilities
Favorite
8:00 AM – 1:30 PM
CEST
(280) Pregnancy and Fetal Outcomes after Maternal Exposure to Glatiramer Acetate – an Updated Analysis
Favorite
8:00 AM – 1:30 PM
CEST
(281) Progress Towards Enrollment in a US Pregnancy Registry for Galcanezumab and Lasmiditan
Favorite
8:00 AM – 1:30 PM
CEST
(282) Reason for gabapentinoids prescribing in pregnancy: results from five European countries. A contribution from the IMI ConcePTION project
Favorite
8:00 AM – 1:30 PM
CEST
(283) Trends in antidepressant use during early pregnancy in Germany between 2005 and 2020
Favorite
8:00 AM – 1:30 PM
CEST
(284) Attitudes and barriers to deprescribing in general practice: the perspective of general practitioners.
Favorite
8:00 AM – 1:30 PM
CEST
(285) Clinical Pharmacist-Led Medication Review in Post-Acute Care: Preliminary Results of an Observational Retrospective Study
Favorite
8:00 AM – 1:30 PM
CEST
(286) Description of interventions performed by pharmacists involved in the care of older adults with neurocognitive disorders in family medicine groups in Quebec, Canada
Favorite
8:00 AM – 1:30 PM
CEST
(287) EHR-based pragmatic trial evaluating the impact of simulation intervention on high-risk prescribing to older adults by junior physicians
Favorite
8:00 AM – 1:30 PM
CEST
(288) Exploring community pharmacy services in the Gulf Region: a scoping review
Favorite
8:00 AM – 1:30 PM
CEST
(289) Highlighting The Role Of The Pharmacist In The Management Of Medication Shortages – An Exploratory Mapping Exercise To The Core Competency Framework For Pharmacists
Favorite
8:00 AM – 1:30 PM
CEST
(290) Impact of Community Pharmacist-Led Services in the Global Fight Against HIV/AIDS: A Systematic Review
Favorite
8:00 AM – 1:30 PM
CEST
(291) Interest in Use of a Mobile App for Reporting Adverse Drug Reactions: A Survey Study Among Healthcare Professionals and the Public in Indonesia
Favorite
8:00 AM – 1:30 PM
CEST
(292) Knowledge and Barriers in Medication Adherence and Prescription Appropriateness Tools: A Cross-Sectional Study in Clinical Practice
Favorite
8:00 AM – 1:30 PM
CEST
(293) Nurses’ intention to report adverse drug events, a survey using the theory of planned behavior.
Favorite
8:00 AM – 1:30 PM
CEST
(294) Optimization of Commercial Clinical Decision Support System for Inpatient Pharmacy at a Medical Center in Taiwan
Favorite
8:00 AM – 1:30 PM
CEST
(295) Physicians' Attitudes Towards Initiatives to Enhance the Environmental Sustainability of Pharmaceutical Treatment
Favorite
8:00 AM – 1:30 PM
CEST
(296) Primary Care Physicians’ Views on Drug Interaction Alerts – a Questionnaire Study
Favorite
8:00 AM – 1:30 PM
CEST
(298) Are Costs Decisive in the Incorporation of Medicines for the Treatment of Ultra-rare Diseases in Brazil? Trends in Healthcare Coverage for Ultra-rare Diseases
Favorite
8:00 AM – 1:30 PM
CEST
(299) Assessing the agreement between open and closed medical claims in a rare disease cohort
Favorite
8:00 AM – 1:30 PM
CEST
(300) Assessing the feasibility of TREAT-NMD registries for characterising adult patients with SMA receiving risdiplam treatment
Favorite
8:00 AM – 1:30 PM
CEST
(301) Can riluzole use for motor neuron disease reduce risk of hospitalisation: A common data model study using Self-Controlled Case Series
Favorite
8:00 AM – 1:30 PM
CEST
(302) Canadian Pustular Psoriasis Study (CAPPS): Examining disease burden, treatments and healthcare resource utilization for palmoplantar pustulosis in Canada
Favorite
8:00 AM – 1:30 PM
CEST
(303) Estimation of period-based costs associated with individual chronic complications of rare inherited diseases, in the context of multimorbidity, using real-world data.
Favorite
8:00 AM – 1:30 PM
CEST
(304) Healthcare resource utilization among patients with multiple system atrophy in US claims database
Favorite
8:00 AM – 1:30 PM
CEST
(305) High Misclassification of Glycogen Storage Disease Type 1a in a US Electronic Medical Records Database – Insights from a Physician Note Review
Favorite
8:00 AM – 1:30 PM
CEST
(306) Incident Treatment and Adverse Liver Outcomes among Patients with Primary Sclerosing Cholangitis: An Analysis of Real-World Data
Favorite
8:00 AM – 1:30 PM
CEST
(307) Long-term Safety and Effectiveness of Taliglucerase-alfa for Gaucher disease (GD): An International, Prospective 10-Year Follow Up Drug Registry Study (TALIAS)
Favorite
8:00 AM – 1:30 PM
CEST
(308) Prevalence, Comorbidities, and Healthcare Costs of Rare Genetic Diseases in Germany: A Claims Database Study
Favorite
8:00 AM – 1:30 PM
CEST
(309) Race and sex differences in healthcare resource utilization among patients with myasthenia gravis in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(310) Retrospective Chart Review Data Collection to Generate External Comparator Arm Populations: Considerations and Suggestions for Reducing Key Biases
Favorite
8:00 AM – 1:30 PM
CEST
(311) Sickle Cell Disease: Comorbidities, Treatment Patterns, and Healthcare Resource Utilization
Favorite
8:00 AM – 1:30 PM
CEST
(312) Strategy for identifying data sources in a rare disease through data landscaping and maximizing the usefulness of the results for researchers
Favorite
8:00 AM – 1:30 PM
CEST
(313) To be an Orphan Disease or Not to Be: An Evaluation of Prevalence Estimates for Cancers Near the Orphan Status Threshold and Implications for Orphan Drug Planning
Favorite
8:00 AM – 1:30 PM
CEST
(314) Treatment of systemic lupus erythematosus: analysis of treatment patterns in adult and paediatric patients across four European countries
Favorite
8:00 AM – 1:30 PM
CEST
(315) Treatments of multiple myeloma in Europe from 2012 to 2022: a population-based network cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(316) Understanding the Prevalence of Transthyretin Amyloidosis (ATTR) in Europe: A Comprehensive Literature Review
Favorite
8:00 AM – 1:30 PM
CEST
(317) Use of European rare disease registries to describe the natural history and disease progression of Spinal Muscular Atrophy (SMA) over time
Favorite
8:00 AM – 1:30 PM
CEST
(318) Comparative effectiveness and safety of single-inhaler triple therapy for COPD
Favorite
8:00 AM – 1:30 PM
CEST
(319) Continuity of care in primary care for young children with asthma: a population-based cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(320) Cost-effectiveness of triple therapy compared to dual therapy in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis
Favorite
8:00 AM – 1:30 PM
CEST
(321) DARWIN EU® - Background Rates of Outcomes of Interest in Patients with Severe Asthma
Favorite
8:00 AM – 1:30 PM
CEST
(322) Efficacy and safety of biologics in asthma and chronic rhinosinusitis with nasal polyps: a systematic review
Favorite
8:00 AM – 1:30 PM
CEST
(323) High Systemic Corticosteroid Burden Among Patients with Uncontrolled Moderate-to-severe Asthma in the US
Favorite
8:00 AM – 1:30 PM
CEST
(324) Identification of Individuals with Severe Asthma in United States Claims Data
Favorite
8:00 AM – 1:30 PM
CEST
(325) Impact of elexacaftor/tezacaftor/ivacaftor on hospital healthcare resource utilization in cystic fibrosis: Danish nationwide register study
Favorite
8:00 AM – 1:30 PM
CEST
(326) Sex differences in the risk of exacerbations among patients with chronic obstructive pulmonary disease: a population-based cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(327) The Fracture Risk of Asthma Patients with Low Bone Mineral Density: Hospital-Based Cohort Study in Taiwan
Favorite
8:00 AM – 1:30 PM
CEST
(328) A Comprehensive Review and Meta-analysis of COVID-19 Vaccine Studies in Vulnerable Populations- Analysis of 126 observational and clinical trials up to November 2022
Favorite
8:00 AM – 1:30 PM
CEST
(329) A Population Database Analysis To Estimate The Varicella Vaccine Effectiveness In Children <14 Years In A High Vaccination Coverage Area From 2004 To 2022
Favorite
8:00 AM – 1:30 PM
CEST
(330) A population-based observational study of determinants of varicella vaccination in the private market in Denmark
Favorite
8:00 AM – 1:30 PM
CEST
(331) Active Safety Monitoring of COVID-19 Vaccines in France using Patient-Reported Outcomes
Favorite
8:00 AM – 1:30 PM
CEST
(332) Background Rates of Neuroinflammatory Disorders and Atrial Fibrillation – Conditions of Interest for Vaccine Safety Studies
Favorite
8:00 AM – 1:30 PM
CEST
(333) Case Series Analysis of Immune-Mediated Neurological Events in Vaccinees following AZD1222 (ChAdOx1 nCoV-19): Results from a UK Post-authorisation Active Surveillance Study
Favorite
8:00 AM – 1:30 PM
CEST
(334) Characterization of COVID-19 vaccine data in the Sentinel System
Favorite
8:00 AM – 1:30 PM
CEST
(335) Claims Profile Review to Assess Age at Vaccination Among Young Males Who Appeared to Receive the 4-valent Human Papillomavirus (HPV) Vaccine (4vHPV vaccine) in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(336) Comparing disparities in uptake of COVID-19 and influenza vaccination among pregnant women, September 2020 and March 2022: English and Welsh national cohorts
Favorite
8:00 AM – 1:30 PM
CEST
(337) Comparison of Influenza and COVID-19 Vaccine Coverage Rates by Age in Selected Geographies During the 2022-2023 Season
Favorite
8:00 AM – 1:30 PM
CEST
(338) Cumulative Rates of Serious and Adverse Events of Special Interest in Vaccinees Following AZD1222 (ChAdOx1 nCoV-19): Results from a UK Post-authorisation Active Surveillance Study
Favorite
8:00 AM – 1:30 PM
CEST
(339) Data mining for adverse events of influenza vaccine in children using a tree-temporal scan statistic analysis
Favorite
8:00 AM – 1:30 PM
CEST
(340) Differences in self-reported adverse events after the first mRNA COVID-19 vaccination between pregnant and non-pregnant women
Favorite
8:00 AM – 1:30 PM
CEST
(341) Early use of Moderna’s mRNA-1273.815 monovalent vaccine: a descriptive analysis of a US Claims database
Favorite
8:00 AM – 1:30 PM
CEST
(342) Effectiveness of BNT162b2 and CoronaVac in individuals with multimorbidity: a territory-wide case-control study
Favorite
8:00 AM – 1:30 PM
CEST
(343) Effectiveness of Maternal mRNA COVID-19 Vaccination Against COVID-19 Symptomatic Infection and Hospitalization in Infants Aged < 6 Months During the SARS-CoV-2 Omicron-Predominant Period: VENUS Study
Favorite
8:00 AM – 1:30 PM
CEST
(344) Effectiveness Of Pertussis Vaccines In Children Between 2013 And 2019 In France: A Nested Matched Case Control Study Using The National Health Data System
Favorite
8:00 AM – 1:30 PM
CEST
(345) Effectiveness of primary COVID-19 vaccination against severe infection in pediatrics: a cohort study using two linked data sources in Spain.
Favorite
8:00 AM – 1:30 PM
CEST
(346) Immunization Status of Rotavirus Vaccine among Infants in Korea
Favorite
8:00 AM – 1:30 PM
CEST
(347) Interim Utilization Results from a Post-Approval Safety Study of Pfizer-BioNTech Monovalent COVID-19 Vaccine in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(348) MotherToBaby Pregnancy Studies, Vaccines in Medications Surveillance System (VAMPSS) COVID-19 Vaccines Study
Favorite
8:00 AM – 1:30 PM
CEST
(349) Observed versus Expected Analysis of Adverse Events of Special Interest after AZD1222 (ChAdOx1 nCoV-19) Vaccination: Results from a UK Post-authorisation Active Surveillance Study
Favorite
8:00 AM – 1:30 PM
CEST
(350) Pilot study on the application of rapid cycle analysis method for post-marketing active vaccine safety surveillance using COVID-19 vaccines in Japan: the VENUS Study
Favorite
8:00 AM – 1:30 PM
CEST
(351) Rates of SARS-CoV-2 Breakthrough Infection or Severe COVID-19 and Associated Risk Factors After Primary and Booster Vaccination Against COVID-19 in the Netherlands
Favorite
8:00 AM – 1:30 PM
CEST
(352) Safety of Ancestral Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 Vaccines in US Children Aged 6 months to 17 years
Favorite
8:00 AM – 1:30 PM
CEST
(353) Serious Neurological Adverse Reactions to SARS-CoV-2 Vaccines in Chile
Favorite
8:00 AM – 1:30 PM
CEST
(354) Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis after COVID-19 Vaccination
Favorite
8:00 AM – 1:30 PM
CEST
(355) Tetanus, Diphtheria, Pertussis (Tdap) Vaccination During Pregnancy and Initiation of Human Milk Feeding
Favorite
8:00 AM – 1:30 PM
CEST
(356) The Persistence in Risk and Effect Of COVID-19 Vaccination on Long-Term Health Consequences One Year After SARS-Cov-2 Infection: A Territory-Wide Cohort Study in Hong Kong
Favorite
8:00 AM – 1:30 PM
CEST
(357) The Use of Background Incidence Rates to Support Vaccine Safety Monitoring: Challenges and Future Opportunities in the Framework of Beyond COVID Monitoring Excellence (BeCOME)
Favorite
8:00 AM – 1:30 PM
CEST
(358) Use of test-negative designs in pharmacoepidemiology: focus on vaccine effectiveness 2013-2023
Favorite
8:00 AM – 1:30 PM
CEST
(359) Vaccination Use among Pregnant Women 2016-2023: An Analysis Using Healthcare Claims
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT01) Medication non-adherence and risk of mortality among patients with incident heart failure: a cohort study using the Clinical Practice Research Datalink (CPRD) Aurum database
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT02) Gender Differences in Statin Persistence across Racial and Ethnic Groups among Persons with HIV in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT03) Implementation of Clinical Pharmacist’s Services in Patients Receiving Oral Oncolytics and its Effects on Medication Adherence and Quality of Life: A Hospital-Based Prospective Interventional Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT04) Socioeconomic and demographic groups associated with adherence to antidiabetic medications in individuals with type 2 diabetes: A nationwide cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT05) Effect of long-acting injectable antipsychotics on treatment adherence and healthcare utilization in Chinese patients with schizophrenia: 1-year mirror-image study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT06) Comparative Analysis of Treatment Discontinuation Among P2Y12 receptor inhibitors Post-Acute Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials.
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT07) Factors Associated with Adherence to Long-Acting Injectable Antipsychotics Among Medicare Beneficiaries
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT08) The Relationships Between ADHD/ADHD Medication and the Persistence of Anti-Hypertensive Medication?
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT09) Evaluating the Association of Denosumab versus Bisphosphonates on Diabetes Risk: A Nationwide Cohort Study and Meta-Analysis
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT10) Effectiveness and Safety of SGLT2 Inhibitor Treatment on Renal Outcomes in Patients with Type 2 Diabetes: A Nationwide Observational Cohort Study in South Korea
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT11) Association between N-acetylcysteine and risk of acute cardiovascular events in illicit substance users: nationwide case-case-time-control study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT12) Effectiveness of everolimus on transplant outcomes in Korean liver transplant recipients: a nationwide cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT13) Association between Antipsychotic Therapy and Suicide Risk in Patients with Treatment-Resistant Depression – A clone-censor-weight Approach to Address Immortal Time Bias
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT14) Multinational prescribing trends of lithium from 2001 to 2019: a retrospective observational study using population-based databases from 17 countries and one special administrative region
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT15) Impact of antithrombotics on the association between proton pump inhibitors and ischaemic stroke: standard and modified self-controlled case series
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT16) Association Between Sacubitril/Valsartan and Risk of Dementia in Heart Failure Patients: A Nationwide Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT17) A post-authorization safety study of golimumab in ulcerative colitis using the Spanish ENEIDA registry (MK8259-042)
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT18) Socioeconomic Conditions Effects On Biological Prescriptions For Inflammatory Bowel Disease In Brazil
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT19) Tree-based mining of real-world data for potential safety signals associated with the use of dupilumab in the United States (2017-2023)
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT20) Adherence Differences Between Self-Administered and Provider-Administered Biologics Among Patients with Rheumatoid Arthritis During the COVID-19 National Emergency
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT21) The Risk of Venous Thromboembolism in Two of the Most Common Inflammatory Skin Diseases - a Comparative Cohort Study Consisting of the Adult Populations of Atopic Dermatitis and Psoriasis in the Swedish Specialist Care
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT22) Biologic Drugs Use In Inflammatory Bowel Diseases: A Systematic Review And Meta-Analysis
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT23) An Active Safety Surveillance Using Real-World Evidence (ASSURE) Approach to Pharmacovigilance Signal Evaluation: The case of infliximab and alternative autoimmune conditions
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT24) Trajectories of adherence to biological drugs in patients with inflammatory bowel diseases: the VALORE project
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT25) Discrete Choice Experiment (DCE) as A Tool to Elicit Patient Preferences in A Complex Benefit-Risk Evaluation: A Rimonabant Case Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT27) A Comparative Analysis of Imposed Post-Authorization Measures for Advanced Therapy Medicinal Products Approved Between 2009-2013 in Europe and in United States of America
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT28) Limited impact of Direct Healthcare Professional Communications when using optimal outcomes and appropriate study populations: a systematic review.
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT29) Assessing use of the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies (RIMES) checklist in risk minimization evaluation studies in the EUPAS register
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT30) Identifying regulatory outcomes of Multi-Database and non- Multi-Database non-interventional Post Authorisation Safety Studies using publicly available information
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT31) Perspectives of People With Type 2 Diabetes Mellitus Towards a Decision Aid Assessing Preferences of Glucose-Lowering Drugs: The Dilemma of Choosing
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT32) Impact of risk communication on thrombosis with thrombocytopenia syndrome for COVID-19 adenovirus vector vaccines on European healthcare professionals
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT33) Incidence, Prevalence, and Survival of Breast Cancer in the United Kingdom from 2000-2021: A Population-Based Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT34) Bruton's Tyrosine Kinase-Induced Musculoskeletal Disorders: A Real-World Safety Data Analysis of FAERS Database and Meta-Analysis of Randomized Controlled Trials
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT35) Live birth rate in female breast cancer survivors compared with the general population: matched cohort study using linked UK electronic health records
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT36) Real-world Treatment Pattern and Overall Survival of Stage III and IV Non‑Small‑Cell Lung Cancer Patients: An Analysis using German Cancer Registry Data
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT37) Use of anthracyclines and trastuzumab in breast cancer patients with comorbid cardiovascular disease in Sweden: a cross-sectional study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT38) Do Multimorbidity, Polypharmacy, and Socioeconomic Position Interact to Increase Colorectal Cancer Mortality? A Danish Nationwide, Population-Based Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT39) Trajectories of Antidepressant Use After Tamoxifen Initiation Among Young and Middle Age Women with Breast Cancer
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT40) Use and Outcomes of Trastuzumab Deruxtecan in HER2-positive and HER2-low Metastatic Breast Cancer in Real-World Setting: A Nationwide Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT41) Effectiveness of Axicabtagene Ciloleucel versus Conventional Treatments as First-line Therapy in Patients With High-risk Large B-cell Lymphoma: a Retrospective External Comparator Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT42) Stem Cell Therapy in Avascular Necrosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT43) Risk Management of Authorised Advanced Therapy Medicinal Products in the EU
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT44) Planned and Ongoing EMA-mandated Post-approval Observational Studies of Cell & Gene Therapies (CGT): What Can We Learn from Study Characteristics?
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT45) Post-marketing Safety Assessment of CAR T-cell Therapies: Analysis of Individual Case Safety Reports in the VigiBase
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT46) Comparative Effectiveness of Denosumab versus Bisphosphonates among Treatment-Experienced Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT47) Do Selective Serotonin Reuptake Inhibitors differ in depression treatment outcomes in Older Adults with Chronic Somatic Diseases? Evidence from a Danish Target Trial Emulation Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT48) Comparative Risk of Neurodevelopmental Disorders Between Children Exposed to β-lactam and non-β-lactam Antibiotics During Gestation: An Emulated Target Trial
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT49) Comparative Effectiveness of Denosumab versus Zoledronic Acid among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT50) No Elevated Risk of Cataract in Amiodarone Users: A Population-based Active-Comparator Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT51) Central vs. Non-central Angiotensin Converting Enzyme-inhibitors and the risk of Alzheimer's disease: A cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT53) Comparison of Anemia Outcomes between SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Patients with Chronic Kidney Disease: Multi-institutional Cohort Study with Target Trial Emulation in Taiwan
Favorite
